The race to stymie BTK: Zanu zings

Prashant Kapoor, Steven P. Treon

Research output: Contribution to journalReview articlepeer-review

Abstract

This issue of Blood presents a tour de force: Trotman and colleagues1 report a phase 1/2 trial of zanubrutinib, a novel Bruton tyrosine kinase (BTK) inhibitor, and lay the groundwork for Tam et al.2 to present a head-to-head comparison of 2 BTK inhibitors, zanubrutinib and ibrutinib, in MYD88L256P mutantWaldenström macroglobulinemia (WM). These companion articles on zanubrutinibwill arguably have broad implications in WM therapeutics. The 2 trials showcase how extraordinary international collaborative efforts were instrumental in the development of zanubrutinib at warp speed for treatment of a rare B-cell malignancy.

Original languageEnglish (US)
Pages (from-to)1997-1999
Number of pages3
JournalBlood
Volume136
Issue number18
DOIs
StatePublished - Oct 29 2020

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'The race to stymie BTK: Zanu zings'. Together they form a unique fingerprint.

Cite this